Information  X 
Enter a valid email address

Tiziana Life SciencesPLC Ord3P (TILS)

Related News

24-Sep-2018 01:42 PM

Tiziana Life Sciences posts loss on R&D spending

Cancer and autoimmune disease focused Tiziana Life Sciences posted a first-half loss as it continued to invest in research and development. Net losses for the six months through June amounted to £3.9m, in line with a loss of £3.9m on-year. T
19-Apr-2018 08:05 AM

Tiziana raises £825,000

Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, has raised £825,000 in cash by the issue of 1,031,250 new ordinary shares at a price of 80p per share. In addition, the com
16-Aug-2017 08:19 AM

Tiziana converts loan notes to shares

Tiziana Life Sciences, a clinical stage biotechnology company, said holders of the company's convertible loan note (CLN) have passed the resolutions to convert all of the loan notes to shares. It was proposed that CLN holders be offered an additiona
07-Jun-2016 07:34 AM

Tiziana Life Sciences widens FY pretax loss

Tiziana Life Sciences has widened its FY pretax loss to £8.6m, from £3.4m. Research and development costs weighed in at £6.3m, from £0.8m. Chair Gabriele Cerrone said 2015 was an important year for Tiziana as the company continued
05-Jun-2015 07:41 AM

Tiziana Life Sciences posts FY pretax loss

Tiziana Life Sciences has posted a FY pretax loss of £3.6m, from nil in the prior year. Revenue was nil. Operating loss was £3.3m. Story provided by
23-Jan-2015 02:15 PM

Tiziana unveils board changes

Tiziana Life Sciences has appointed Professor Christopher McGuigan and Dr Kunwar Shailubhai as non-executive directors and that Andrew Gutmann has resigned from the board. McGuigan is chairman of Life Sciences Hub Wales Limited, professor of Medicinal Ch

a d v e r t i s e m e n t